Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
National Institutes of Health (NIH)
Medivation, Inc.
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Jacalyn Rosenblatt, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01096602
First received: March 29, 2010
Last updated: August 30, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)